Abstract: Testicular cancer is rare but is the most common cancer in males between 15 and 34 years of age. Two principal types of testicular cancer are distinguished: seminomas and non-seminomas. If detected early, the overall cure rate for testicular cancer exceeds 90%. In this study, artificial neural network (ANN) analysis as a prognostic tool was demonstrated regard to five year recurrence after the non-seminoma treatment. Data from 202 patients treated for non-seminoma were available for evaluation and comparison. A total of 32 variables were analysed using the ANN. The ANN approach, as an advanced multivariate data processing method, was demonstrated to provide objective prognostic data. Some of these prognostic factors are consistent or even imperceptible with previously evaluated by other statistical methods.
Introduction
Although testicular cancer is rare, accounting for only 1% of all male cancers, it is most common in males aged 15 to 34 years [1] . In Poland, 617 males (incidence rate 2.9 per 100,000) were diagnosed with the malignancy and 122 of them (fatality rate 0.6 per 100,000) died [2] . Most cases of testicular cancer (90-95%) originate from the germinal epithelium. Seminomas and non-seminomas are the two major histologic groups of germ cell tumours and account for 25% and 75% of all testicular tumours, respectively. Non-seminomas include the following histologic subtypes: embryonal carcinoma, choriocarcinoma, yolk sac tumour and teratomas [3] .
The most common risk factors of this disease include: a family history of testicular cancer, contralateral testicular cancer, testicular torsion, Klinefelter's syndrome, cryptorchidism and testicular dysgenesis [4] . The diagnostic evaluation for testicular cancer includes medical history, physical examination, ultrasound and biopsy. Radiography, computed tomography (CT), magnetic resonance imaging (MRI) and blood tests, including such tumour markers as alpha-fetoprotein (AFP), beta-subunit of human chorionic gonadotropin (βhCG), human chorionic gonadotropin (hCG) and the less specific lactate dehydrogenase (LDH), are performed to determine the stage of the disease and the potential presence of metastases [5] .
According to the National Cancer Institute classification, the stages of testicular cancer include: stage I -the caner is limited to the testis, stage II -the cancer has spread to the lymph nodes in peritoneal cavity, stage III -the cancer has spread to the lymph nodes outside the peritoneal cavity or to other organs [6] . Standard treatment of testicular cancer includes orchidectomy followed by adjuvant chemotherapy in the case of nonseminomas and radiochemotherapy for seminomas. Because of the 12-fold higher risk of developing a contralateral tumour in men with a unilateral diagnosis, biopsy of the contralateral testicle at the time of orchiectomy is recommended [7, 8] . Data from 41 population-based cancer registries worldwide as regards testicular nonseminomas and seminomas have been emphasised in recent papers [9] .
Metastatic testicular germ cell tumours can be cured with cisplatin-based combination chemotherapy. These particular tumours are curable because of the direct response of the tumour cells to DNA-damaging agents. Most males with metastatic testicular germ cell tumours have a normal lifespan after they survive 5 years in contrast to patients with other types of metastatic cancer. Despite the relatively favourable prognosis, even in the advanced stages of the disease, individual patient's survival might be problematic.
With regard to different types of data, pathological, clinical and molecular parameters the statistical models can be useful tools in clinical practice because they offer a valuable insight into the survival process [10] . Several attempts to employ computational modelling techniques in clinical practice have been reported [11] . However, the lack of the effective methods to predict disease recurrence or progression has led to the search for methods that combine the existing clinical, pathological and laboratory data with complex mathematical models [12] . Hence the growing interest in artificial neural network (ANN) analysis in establishing the diagnosis and prognosis in urology and oncology [13, 14] . This technique is an advanced multivariate data processing method whose uses increase every year in various areas of science. ANN is a mathematical model based on biological neural networks. As an adaptive (learning) system, it can be used for modelling relationships between inputs and outputs or to find patterns in data. However, ANN is often incorrectly used by oncologists and the involvement of an experienced statistician is advisable [15, 16] . Thanks to their specific learning ability ANNs have certain advantages over classical computational modelling techniques [17] . The most important advantage is their ability to generate data-driven models of biological systems without making assumptions based on statistical distributions. The ability of ANNs to perform pattern recognition quickly and accurately was utilised in the modelling of structure-activity relationships of chemical compounds, identification of potential drug targets, localisation of structural and functional features of compounds [18] [19] [20] .
There has been an increasing interest recently in applying ANNs in clinical practice, especially oncology and urology [21] [22] [23] [24] . ANNs have also been used as a tool to diagnose and predict the stage of prostate cancer and non-seminomatous testicular cancer [25] [26] [27] . The "artificial intelligence technique" is a useful method, which may be combined with MRI and ultrasound in order to obtain an accurate diagnosis estimating the stage of the disease with the view to a better planning of treatment in urological cancers [28] [29] [30] [31] [32] .
The aim of this study was to perform an effective and modern data processing method, as a prognostic tool in predicting recurrence within a five-year period after treatment of non-seminoma testicular cancer.
Materials and methods

Patient characteristics
A 5-year follow-up data from 202 patients treated for non-seminoma were available for evaluation and comparison. A total 32 variables presented in Table 1 were included in the ANN analysis.
The study was based on retrospective data collected between 2007-2008 from three facilities: the Greater Poland Cancer Centre in Poznan, a urology department and a general hospital.
Patients (from 17 to 74 years of age) were treated with chemotherapy between 1995 and 2002. The classification of patients with histopathologically diagnosed testicular cancer was established according to the WHO criteria. The use of chemotherapy depended on the patient's condition and tumour stage. The primary choice of treatment included PVP (cisplatin/vinblastine/bleomycin) in 67 patients (33.17%) and BEP (bleomycin/etoposide/cisplatin) in 135 (66.83%) patients.
Staging and the assessment of the treatment response were based on imaging studies (ultrasound and CT). After every third cycle of chemotherapy the levels of AFP and βhCG were determined. Patients were monitored for recurrence every three months, followed by every six months for five years after the applied treatments.
ANN Analysis
Data Miner (StatSoft, Tulsa, USA), was used to perform the ANN analysis. In the first step of analysis, the data of 202 non-seminoma patient were randomly divided into three sets: the learning, validating and testing sets with Table 2 ). The output data (treatment result) were presented as two-state nominal variables (no recurrence [1] and recurrence [2] ).
In the next phase, an ANN based on a multilayer perceptron was built. The input layer consisted of 54 neurons of linear aggregation and activation function. This layer presented 32 variables. Eighteen artificial neurons formed the hidden layer of linear aggregation and hyperbolic activation function. The output layer consisted of 1 neuron of linear aggregation and logistic activation function. The applied ANN model is presented in Figure 1 .
Prior to the two-phase learning process the network's weights were randomised. For the first 399 epochs the Back Propagation (BP) method was used. The RMS error values were recorded for the learning and validating data sets during the training process. Further efforts did not improve the network performance; on the contrary, they caused over-fitting. Figure 2 shows a simultaneous decrease of RMS error for the learning set with an increase of RMS error for the validating set close to the thousandth epoch. The trained and validated ANN was taken for further investigation -testing process. Classification statistics for the training, validating and testing sets are summarised in Table 3 . In Figure 3 , Receiver Operating Characteristic (ROC) curves are presented with the values of areas for all of the sets we used. Figure 1 presents the architecture of the ANN used for the prediction of non-seminoma recurrence within a five-year period after treatment. The results of classification statistics obtained by ANN in the testing group as with and without five year recurrence with a prognostic potency of more than 94% are presented in Table 3 . Fifty patients in the testing set of total number of 47 were correctly classified.
Results
In order to estimate the importance of the variable obtained in the ANN model we used on the prediction of recurrence we performed a sensitivity analysis for input variables. This analysis provides an important insight into the usefulness of each variable and distinguishes which parameters are most significant (with the rank close to 1) and least significant (with the rank close to 32) ( Table 4 ). According to the sensitivity analysis, the treatment response is the most significant parameter for distinguishing patients with and without non-seminoma recurrence. Also, such variables as anaemia, vascular invasion and metastasis are highly significant. Educational background and the place of residence are the most interesting and significant variables. 
Statistics
Learning 
Discussion
The officially recognised and used classification of prognostic factors for use in clinical practice was developed by the International Germ Cell Cancer Collaborative Group (IGCCCG). According to the IGCCCG guidelines, the levels of the serum tumour markers LDH, AFP and βhCG immediately before chemotherapy play a crucial role as a prognostic factor to determine the stage of the disease and the potential presence of metastases. Also, patient age, time from the occurrence of symptoms to hospital admission, number of metastases, histologic type and tumour size are recommended as significant parameters that may be associated with the recurrence rate. Presently, the following prognostic classification after treatment of nonseminoma in clinical practice is used: good, intermediate and poor prognosis. The classification takes into account serum levels of tumour markers, primary location of the tumour, histologic type and the presence or absence of non-pulmonary visceral metastases. In this study, the parameters recognised by the IGCCCG, treatment history and demographic data were evaluated in the ANN analysis for the prediction of recurrence after a five-year period after treatment of non-seminoma.
The analysis of the selected factors was not carried out in the clinical study setting but was based on retrospective data. The analysis was based on demographic parameters and those related to the biology of cancer, i.e. factors the patient and his doctor have no influence on. In our study, using sensitivity analysis, we also attempted to identify parameters dependent on the so-called human factor. We demonstrated that such parameters as treatment modification, primary choice of treatment and place of surgery were significant for prediction of recurrence within a five-year period after treatment of non-seminoma testicular cancer. The sensitivity analysis showed that treatment response was of greatest significance. Metastatic testicular germ cell tumours are sensitive to cisplatin-based chemotherapy. PVB, BEP and EP regimens lead to cure with the survival rates of 98%, 95% and 80% for stage I, II and III disease, respectively. In a large number of patients at high risk of recurrence, the tumour is curable after the treatment of choice: chemotherapy. However, most patients in whom the cancer recurred died after a short period of time.
Cisplatin-based chemotherapy leads to nearcomplete remission but also increases the risk of the adverse reactions. As regards the sensitivity analysis anaemia (Rank 2) is the second significant parameter which may also be caused by various factors, such as chronic kidney disease, bone marrow malignancies and abnormal secretion of erythropoietin associated with cisplatin therapy. The treatment response, anaemia, vascular invasion and metastasis are evident from the clinical point of view. The high sensitivity coefficient obtained for the "educational background" means that testicular cancer patients with a college or university education are less likely to experience recurrence.
Based on the sensitivity analysis some of the significant variables are different from the prognostic factors proposed by IGCCCG and described in literature.
Conclusion
Determination of prognosis in caner is of fundamental importance for the doctor as well as for his patient. Prognostication in cancer is determined very generally for a given group of patients. Experienced clinicians go beyond statistics and are guided by number of additional features (intuition). The prognostic statistical tool is an attempt to perform a statistical objectification of such preconscious action and enables prediction of prognosis in individual cases with an accuracy of 94%.
